Building an RWD Oncology Data Mart for Diffuse Large B-Cell Lymphoma: From Data Integration to Clinical Insight.

INTRODUCTION

Diffuse Large B-Cell Lymphoma (DLBCL) is a heterogeneous and aggressive non-Hodgkin lymphoma, marked by wide variability in clinical presentation, biological profile, and disease course. Real World Data provide a unique opportunity to capture this complexity, offering insights into patient characteristics, disease progression, and outcomes in routine practice.

METHODS

This study describes the development of a DLBCL-specific Data Mart that integrates heterogeneous demographics, laboratory, histopathological, therapeutic and progression data into a standardized framework. The system supports automated identification of treatment lines and reconstruction of longitudinal patient histories, incorporating chemotherapy, radiotherapy, relapse and mortality data. An interactive dashboard displays individual disease trajectories over time.

RESULTS

The 1,235 patients Data Mart facilitates systematic analysis of therapies, patient responses, and disease progression, providing a reproducible, scalable platform for Real World Evidence generation.

CONCLUSION

The DLBCL Data Mart demonstrates the potential of Real World Data to support research, inform clinical decision-making, and serve as a model for other oncology domains.